In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...
Read MoreLung cancer Posts on Medivizor
Evaluating the effectiveness and safety of sugemalimab after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.
In a nutshell This study investigated the effectiveness and safety of sugemalimab (Cejemly) after treatment with concurrent or sequential chemoradiotherapy (CRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC). The data showed that sugemalimab significantly increased the survival without cancer worsening with manageable...
Read MoreBiomarkers, Combination Therapy, and Lung Cancer
KRAS, one gene present in some cancers, was considered “undruggable” for years.[1] Mutated KRAS is an important target for patients with non-small cell lung cancer (NSCLC) because it’s present in 20-25% of cases.[2] Finally, one drug, sotorasib (Lumakras), is approved to treat one mutant form of KRAS gene, KRAS G12C.[3] This mutation appears in...
Read MoreEvaluating the effectiveness and safety of first-line tyrosine kinase inhibitor with or without radiotherapy for the treatment of patients with oligometastatic EGFR-mutated NSCLC.
In a nutshell This study evaluated the effectiveness and safety of first-line tyrosine kinase inhibitors (TKIs) with or without radiotherapy (RT) for the treatment of patients with oligometastatic (OM) non-small-cell lung cancer (NSCLC) having genetic mutations in the epidermal growth factor receptor (EGFR). The data showed that TKI plus RT was safe and...
Read MoreEvaluating the effectiveness and safety of sugemalimab plus platinum-based chemotherapy for first-line treatment of metastatic squamous and non-squamous non-small cell lung cancer.
In a nutshell This study investigated the effectiveness and safety outcomes of sugemalimab (Cejemly) in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic squamous (Sq) and non-squamous (non-Sq) non-small cell lung cancer (NSCLC). The data showed that sugemalimab plus platinum-based chemotherapy...
Read MoreEvaluating the effectiveness and feasibility of patient-reported outcome-based symptom management versus usual care in patients after lung cancer surgery.
In a nutshell This study evaluated the effectiveness and feasibility of patient-reported outcome (PRO)-based symptom management versus usual care in patients after lung cancer surgery. The data showed that PRO-based symptom management after lung cancer surgery showed lower symptom burden and fewer complications than usual care for up to 4 weeks after...
Read MoreVacations for Adult Cancer Patients: Update
Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update. Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...
Read MoreEvaluating the effectiveness of immunotherapy in advanced lung cancer with and without brain metastases.
In a nutshell This study evaluated the effectiveness of immunotherapy in advanced lung cancer (LC) patients with and without brain metastases (BMs). The data showed that immunotherapy significantly improved overall survival in LC patients with and without BMs. Some background In 20-40% of patients with advanced LC, the cancer spreads from the lung to...
Read MoreWhich sequence of treatment should be given first – local or systemic treatment for patients with non-small cell lung cancer and brain metastases?
In a nutshell This study evaluated which sequence of treatment should be given first, local or systemic (whole-body) treatment for patients with non-small cell lung cancer (NSCLC) and brain metastases (BMs). The data showed that systemic treatment followed by local treatment was associated with longer survival for patients with NSCLC and BM. Some...
Read MoreIs chemotherapy after surgery followed by atezolizumab a good treatment option in patients with early stage non-small-cell lung cancer?
In a nutshell The study aimed to investigate the effectiveness and safety of atezolizumab (Tecentriq) versus best supportive care after chemotherapy in patients with resected early-stage non-small-cell lung cancer (NSCLC). The study showed atezolizumab is effective and has better outcomes than best supportive in these...
Read MoreCan osimertinib be used as first-line therapy in older patients with EGFR-mutated NSCLC?
In a nutshell This study evaluated the effectiveness and safety of osimertinib (Tagrisso) as first-line therapy for older patients above 75 years with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). The data showed that osimertinib as first-line therapy is effective in these patients. However, osimertinib was...
Read MoreEvaluating the effectiveness and safety of combining proton plus carbon-ion radiotherapy with chemotherapy given at the same time in patients with limited-stage small-cell lung cancer.
In a nutshell This study investigated the effectiveness and safety of combining proton radiotherapy (PRT) plus carbon-ion radiotherapy (CIRT) with chemotherapy (CT) given at the same time in patients with limited-stage (LS) small cell lung cancer (SCLC). The data showed that PRT plus CIRT with CT given at the same time was effective with manageable side...
Read More